I met with Dr. Frederick Ruberg from Boston University to discuss his talk from AHA 2019 titled “HFpEF: It’s a Diagnosis of Exclusion, So Exclude Other Causes!” We discuss what the diagnosis of HFpEF entails and then dive into cardiac amyloidosis and what populations should be screened for amyloid. Links to papers work via apcardiology.com

Links:

Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.

Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis

Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model

I caught up with Dr. James de Lemos from UT Southwestern at the 2019 American Heart Association meeting to discuss a number of updates in acute coronary syndromes. We cover a number of recent trials that are shaping how we think about ACS management from medications, stent deployment and the mechanism we might be overlooking.

Links to articles:

ISAR-REACT 5

TWILIGHT

POPular Genetics

COMPASS

In this episode I visit with Dr. Michelle Kittleson (@MKIttlesonMD) of Cedars-Sinai to discuss evaluation and management of patients admitted with acute decompensated heart failure. We review the etiologies for decompensation, what to do with beta-blockers or RAS inhibitors and how to setup the patient for a successful discharge.

Links to papers:

Effects of Beta-blocker Withdrawal Meta-Analysis

Early worsening renal function after initiation of ACE inhibitor, Testani Circulation Heart Failure 2011

DOSE Trial

Furosemide v Torsemide

PARADIGM-HF

DAPA-HF